12-chloro-5,6,7,12-tetrahydrodibenzocyclooctene | 24295-89-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 12-chloro-5,6,7,12-tetrahydrodibenzocyclooctene
• 英文别名: 5-Chlor-dibenzocyclooctadien；2-Chlorotricyclo[10.4.0.03,8]hexadeca-1(16),3,5,7,12,14-hexaene
• CAS: 24295-89-4
• 化学式: C₁₆H₁₅Cl
• 分子量: 242.748
• InChiKey: GHFDIPMDHOXVPY-UHFFFAOYSA-N

物化性质

• 沸点：
  357.3±41.0 °C(Predicted)
• 密度：
  1.16±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  12-chloro-5,6,7,12-tetrahydrodibenzocyclooctene 生成 Dibenzocyclooctadien-5-carbonsaeureamid
  参考文献：
  名称：

  抗惊厥。I.二苯并（A，D）环庚二烯-5-羧酰胺和相关化合物。

  摘要：

  DOI：

  10.1021/jm00331a019
• 作为产物：
  描述：

  10,11-dihydro-12-H-dibenzo[a,d]cycloocten-5-one 在 盐酸 、 sodium tetrahydroborate 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 12-chloro-5,6,7,12-tetrahydrodibenzocyclooctene
  参考文献：
  名称：

  New triazine derivatives as potent modulators of multidrug resistance

  摘要：

  A series of 70 triazine derivatives have been synthesized and tested for their capacity to modulate multidrug resistance (MDR) in DC-3F/AD and KB-A1 tumor cells in vitro, in comparison with verapamil (VRP), a calcium channel antagonist currently used in therapy as an antihypertensive drug, which also shows MDR modulating activity. Among the 12 selected compounds, 16 (S9788) showed high MDR reversing properties in vitro (300- and 6-fold VRP at 5-mu-M in DC-3F/AD and KB-A1 cells, respectively) and induced a strong accumulation of adriamycin. The relationship between the increase of ADR accumulation and the fold reversal induced by these compounds and their lack of effects on the sensitive DC-3F cells suggest that they act mainly by inhibiting the P-glycoprotein (Pgp) catalyzed efflux of cytotoxic agents, as already described for a majority of MDR modulators. In vivo, in association with the antitumor drug vincristine (0.25 mg/kg), 16 (100 mg/kg) increased the TIC by 39% in mice bearing the resistant tumor cell line P388/VCR. According to these interesting properties, 16 was selected for a clinical development because it was more bioavailable than 34, even though it was less active.

  DOI：

  10.1021/jm00091a017